ClinicalTrials.gg
CompletedNCT05564208Updated Feb 20, 2025

A Study to Evaluate the Effect of Food on the Level of Circulating Elafibranor in Healthy Participants After Intake of a Single Tablet

A Phase 1 interventional study of elafibranor and elafibranor in Healthy Participants, sponsored by Ipsen. Completed at 1 site in France. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-20.

Sponsored by Ipsen · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study will evaluate the effects of food on how much test drug is able to access the circulation and reach the target area (known as bioavailability).

The test drug, elafibranor (IPN60190), is in development for the treatment of primary biliary cholangitis (PBC).

PBC is a rare, long-term autoimmune disease of the liver. An autoimmune disease occurs when the immune (defence) system treats healthy parts of the body as if they were foreign and attacks them.

This study will be in healthy volunteers, so this trial is not to test if the drug helps to improve health.

02

Conditions studied

  • Healthy Participants

Keywords

  • Pharmacokinetics
  • Elafibranor
03

In context

Lead sponsor

Ipsen is the lead sponsor of 289 studies on the registry; 17 are open to participants now.

Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willingness to remain at the clinic for the required duration and willingness to return to the clinic for the follow-up evaluation as specified in the protocol
  • Healthy participants as determined by medical evaluation at the screening visit including medical history, physical examination, laboratory tests, (ECG) and vital signs monitoring
  • Laboratory parameters within the normal range of the laboratory (haematological, blood biochemistry, urinalysis) at screening and baseline visit of each period. Individual values out of the normal range can be accepted if judged not by the investigator
  • Normal electrocardiogram (ECG) recording on a 12-lead ECG at screening and baseline visit of each period:

    • 120≤PR≤220 ms,
    • QRS\<110 ms,
    • ≤430 ms for male and
    • ≤450 ms for female,
  • No evidence of sinus node automaticity or abnormal conduction, or rhythm disorders of concern, except as considered not clinically significant by the investigator. Out-of-range values that are not clinically significant (as determined by the investigator) may be repeated twice during screening and baseline visits of each period and the participant may be enrolled if at least one repeated value is within the range noted above.
  • Normal blood pressure (BP) and heart rate (HR) at screening and baseline visits of each period after 5 minutes in supine position:

    • 90 mmHg≤systolic blood pressure (SBP)≤145 mmHg,
    • 50 mmHg≤diastolic blood pressure (DBP)≤90 mmHg,
    • 45 bpm≤HR≤90 bpm,
  • For these parameters, out-of-range values that are not clinically significant (as determined by the investigator) may be repeated twice during screening and baseline visits of each period and the participant may be enrolled if at least one repeated value is within the range noted above.
  • Body weight not below 55 kg and (BMI) within the range 20.0 kg/m\^2 and 28.0 kg/m\^2 (inclusive) at screening.
  • /barrier requirements: Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. A female participant is eligible to participate if she is not pregnant or breastfeeding at screening, is willing not to become pregnant during the study, and is willing to follow applicable protocol requirements related to this. Male participants are eligible to participate if they agree to follow applicable protocol requirements related to contraception.

Exclusion criteria

Exclusion Criteria :

  • History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, haematological or neurological disorders capable of significantly altering the absorption, metabolism or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data.
  • Lymphoma, leukaemia or any within the past 5 years except basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years prior to screening
  • Breast cancer within the past 10 years at screening
  • Major surgery within 28 days prior to screening
  • Past or intended use of over the counter (OTC) or prescription medication (including herbal medications or vitamin supplements, nutritional supplements, herb-containing drug preparations (including Chinese medicines)) within 14 days or 5 half-lives of the drug (whichever is longer) prior to dosing. Exceptions are oral /hormone replacement therapy for females and paracetamol/acetaminophen at doses of ≤2 g/day.
  • Any vaccination during the 4 weeks before randomisation or planned during the clinical study
  • Use of any medications within 3 months that may interfere with absorption, distribution, metabolism or excretion of the study intervention, or any medication that may result in induction or inhibition of microsomal enzymes.
  • Plasma donation within 14 days of the screening or any blood donation/ blood loss >450 mL during the last 30 days before screening. Blood and/or plasma should not be donated until 30 days after last study intervention.
  • Current enrolment or past participation within the last 3 months (or 5 half-lives, whichever is longer) before signing of consent in any other clinical study involving an study intervention or any other type of medical research.
  • Participant who would receive more than 4500 Euro as indemnities for participation in biomedical research within the last 12 months, including the indemnities for the present study.
  • Presence of surface antigen (HBsAg) at screening
  • Positive antibody test result at screening. NOTE: Participants with positive hepatitis C antibody due to prior resolved disease can be enrolled if a confirmatory negative hepatitis C ribonucleic acid (RNA) test is obtained and sustained viral response can be documented
  • Positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention. NOTE: Test is optional and participants with negative hepatitis C antibody test are not required to also undergo hepatitis C RNA testing
  • Positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen test result at screening or during the study
  • Positive drugs of abuse/alcohol screen at screening and baseline visit of each period
  • Positive (HIV) antibody test at screening
  • Consumption of other foods or beverages (e.g. red wine, Seville oranges, grapefruit orgrapefruit juice (including pomelos, exotic citrus fruits, grapefruit hybrids, or fruit juices)) that may affect drug-metabolising enzymes or transporters from 7 days prior to dosing until the end of each study period
  • Inability to abstain from caffeine- or xanthine-containing products (e.g. coffee, tea, cola drinks and chocolate) for 24 hours before dosing until after collection of the final PK sample in each period
  • Any history or suspicion of alcohol abuse (alcohol consumption >40 g/day). Inability to abstain from alcohol for 24 hours before each period and until after the last sample from each period is collected
  • History of illicit drug abuse within the last 12 months
  • Sensitivity to any components of the study intervention or other allergy that, in the opinion of the investigator, contraindicates participation in the study, including lactose intolerance
  • Inability to abstain from intensive muscular effort. Participants should not engage in any strenuous activity from 72 hours prior to admission to the clinical unit until after their EOS visit
  • Smoker. Smoking or use of tobacco or nicotine-containing products within 3 months prior to or during the study. Status will be confirmed with a urine cotinine at screening and at baseline visits of each period
  • Had been on a diet incompatible with the on-study diet (i.e. unusual meal habits, special diet requirements or unwillingness to eat the food provided in the study, e.g. vegetarian nor vegan), in the opinion of the investigator or designee, within the 30 days prior to the first dosing and throughout the study
  • Venous status at forearm or dorsal hand making it difficult to insert a venous peripheral catheter
  • Vulnerable subjects, e.g. kept in detention, protected adults under guardianship, trusteeship or committed to an institution by governmental or juridical order
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Elafibranor Fasting then Elafibranor fed

    Participants will receive Elafibranor 80 mg in Fasting State on Day 1 of Period 1 followed by a washout period of a maximum of 28 days. Participants will then receive Elafibranor 80 mg in Fed State on Day 1 of Period 2.

    Drug: elafibranor

  • Experimental
    Elafibranor Fed then Elafibranor fasting

    Participants will receive Elafibranor 80 mg in Fed State on Day 1 of Period 1 followed by a washout period of a maximum of 28 days. Participants will then receive Elafibranor 80 mg in Fasting State on Day 1 of Period 2.

    Drug: elafibranor

Interventions

  • Oral Tablet

    Also known as: GFT505, IPN60190

  • Oral Tablet

    Also known as: GFT505, IPN60190

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK) of Elafibranor: Area Under the Plasma Concentration Time Curve From Zero to the Last Quantifiable Concentration (AUC0-t)

    AUC0-t will be recorded from the PK blood samples collected.

    Time frame: Day 1 up to Day 10

  2. PK of Elafibranor: Area Under Plasma Concentration Time Curve From Zero to Infinity (AUC0-∞)

    AUC0-∞ will be recorded from the PK blood samples collected.

    Time frame: Day 1 up to Day 10

  3. PK of Elafibranor: Maximum Observed Plasma (peak) Drug Concentration (Cmax)

    Cmax will be recorded from the PK blood samples collected.

    Time frame: Day 1 up to Day 10

Secondary outcomes

  1. PK of Elafibranor's Metabolite GFT1007: Area under the Plasma Concentration Time Curve From Zero to the Last Quantifiable Concentration (AUC0-t)

    AUC0-t will be recorded from the PK blood samples collected.

    Time frame: Day 1 up to Day 10

  2. PK of Elafibranor's Metabolite GFT1007: Area Under Plasma Concentration Time Curve From Zero to Infinity (AUC0-∞)

    AUC0-∞ will be recorded from the PK blood samples collected.

    Time frame: Day 1 up to Day 10

  3. PK of Elafibranor's Metabolite GFT1007: Maximum Observed Plasma (peak) Drug Concentration (Cmax)

    Time frame: Day 1 up to Day 10

  4. PK of Elafibranor and its Metabolite GFT1007: Terminal Elimination Half-life (t1/2)

    t1/2 will be recorded from the PK blood samples collected.

    Time frame: Day 1 up to Day 10

  5. PK of Elafibranor and its Metabolite GFT1007: Time to Maximum Observed Drug Concentration (Tmax)

    Tmax will be recorded from the PK blood samples collected.

    Time frame: Day 1 up to Day 10

  6. PK of Elafibranor and its Metabolite GFT1007: Terminal Elimination Rate Constant (λz)

    tlag will be recorded from the PK blood samples collected.

    Time frame: Day 1 up to Day 10

  7. PK of Elafibranor and its Metabolite GFT1007: Terminal Elimination Rate Constant (λz)

    λz will be recorded from the PK blood samples collected.

    Time frame: Day 1 up to Day 10

  8. PK of Elafibranor and its Metabolite GFT1007: Total Body Clearance (Cl/F)

    Cl/F will be recorded from the PK blood samples collected.

    Time frame: Day 1 up to Day 10

  9. PK of Elafibranor and its Metabolite GFT1007: Volume of distribution (Vd/F)

    Vd/F will be recorded from the PK blood samples collected

    Time frame: Day 1 up to Day 10

  10. Percentage of Participants With Treatment Emergent Adverse Event (TEAEs) and Adverse Events of Special Interest (AESIs)

    An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AESIs are AEs that may not be serious but are of special importance to a particular drug or class of drugs

    Time frame: Baseline up to Day 21

  11. Percentage of Participants With Clinically Significant changes in Laboratory Parameters (blood chemistry, hematology and coagulation)

    Percentage of participants with clinically significant change in laboratory parameters (blood chemistry, hematology and coagulation) will be reported. The clinical significance will be decided by the investigator

    Time frame: Baseline up to Day 21

  12. Percentage of Participants With Clinically Significant Changes in Vital Signs

    Percentage of participants with clinically significant changes in Vital Signs will be reported. The clinical significance will be decided by the investigator.

    Time frame: Baseline up to Day 21

  13. Percentage of Participants with Clinically Significant Changes in 12-lead Electrocardiogram (ECG) Readings

    Percentage of participants with clinically significant changes in ECG readings will be reported. The clinical significance will be decided by the investigator.

    Time frame: Baseline up to Day 21

  14. Percentage of Participants With Clinically Significant Changes in Physical Examination

    Percentage of participants with clinically significant changes in physical examination findings will be reported. The clinical significance will be decided by the investigator.

    Time frame: Baseline up to Day 21

07

Study locations

1 site
  • BIOTRIAL
    Rennes, 35000, France
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Dec 2022, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2022
First posted
Oct 3, 2022
StartActual
Oct 27, 2022
Primary completionActual
Dec 30, 2022
CompletionActual
Jan 14, 2023
Last update
Feb 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05564208
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Oct 3, 2022
Start date
Oct 27, 2022
Primary completion
Dec 30, 2022
Completion
Jan 14, 2023
Last update
Feb 20, 2025

Study contacts

Ipse Medical Director
study director · Ipsen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elifibranor

Start the discussion